Welcome
EpiHeart is a young medical device company, enabling a new therapy for ischemic cardiac scars and heart failure.
About Us
Our Focus
Our Background
Our Background
EpiHeart is dedicated to improve long term survival and quality of life of the patients having Cardiac Artery Bypass Grafting (CABG). Based on intial pre-clinical and clinical results the epicardial transplantation of autologous cells during the CABG surgery reduces the scar tissue and fibrosis causing heart failures
Our Background
Our Background
Our Background
EpiHeart is a spin-off company leveraging over 10 years of dedicated research conducted on three continents. Our home is Helsinki, Finland, where we have deep collaboration with University of Helsinki, Helsinki University Hospital "HUS" and Aalto University.
Collaboration
Our Background
Collaboration
Epiheart is open for collaboration. We foresee collaboration possibilites:
- Clinical studies with European and US clinics performing CABG surgeries.
- Distributors able to serve and interact clinics performing CABG surgeries.
- Life Science / Medical Device Investors
Feel free to request further information on our science, clinical trial program and more.